Efficacy of Everolimus as Inhibitor of Fibrosis Progression in Liver Transplant Patients With Recurrence of Hepatitis C Viral Infection

NCT00582738 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

43

Enrollment

INDUSTRY

Sponsor class

Conditions

Recurrent Hepatitis C

Interventions

DRUG: CsA-TAC (standard Treatment)
DRUG: Everolimus

Sponsor

Novartis Pharmaceuticals